Blood-brain barrier pathology in patients with severe mental disorders: a systematic review and meta-analysis of biomarkers in case-control studies

Abbott, 2010, Structure and function of the blood-brain barrier, Neurobiol. Dis., 37, 13, 10.1016/j.nbd.2009.07.030 Aleksovska, 2014, Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia, PloS One, 9, 10.1371/journal.pone.0106342 American Psychiatric Association, 2013 Ando, 2018, Brain-Specific ultrastructure of capillary endothelial glycocalyx and its possible contribution for blood brain Barrier, Sci. Rep., 8, 17523, 10.1038/s41598-018-35976-2 Arora, 2019, Serum S100B levels in patients with depression, Indian J. Psychiatr., 61, 70 Arostegui, 2016, Biochemical parameters associated with neuroinflammation in depressed patients: relationship with clinical intensity [abstract]. In: 29th ECNP; Austria, Eur. Neuropsychopharmacol, 26, S208, 10.1016/S0924-977X(16)31055-0 Ayyildiz, 2018, Serum S100B levels in patients with major depression and panic disorder, Nobel Medicus, 14, 39 Benros, 2012, Autoimmune diseases and infections as risk factors for schizophrenia, Ann. N. Y. Acad. Sci., 1262, 56, 10.1111/j.1749-6632.2012.06638.x Biron, 2011, Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer’s disease, PloS One, 6, 10.1371/journal.pone.0023789 Bruno, 2017, A neurobiological model of memory impairment in late-life major depressive disorder [abstract], AAIC UK Alzheimer Dement, 13, 1332, 10.1016/j.jalz.2017.06.2049 Cai, 2018, Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation, Mol. Psychiatr. Chen, 2017, Cognitive dysfunction correlates with elevated serum S100B concentration in drug-free acutely relapsed patients with schizophrenia, Psychiatr. Res., 247, 6, 10.1016/j.psychres.2016.09.029 Correll, 2017, Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls, World Psychiatr., 16, 163, 10.1002/wps.20420 Coughlin, 2013, Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia, Mol. Psychiatr., 18, 10, 10.1038/mp.2012.6 da Rosa, 2016, Serum S100B in manic bipolar disorder patients: systematic review and meta-analysis, J. Affect. Disord., 206, 210, 10.1016/j.jad.2016.07.030 Deng, 2017, Elevated plasma s100b, psychotic symptoms, and cognition in schizophrenia, Psychiatr. Q., 89, 53, 10.1007/s11126-017-9514-y Drevets, 2008, Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression, Brain Struct. Funct., 213, 93, 10.1007/s00429-008-0189-x Falcone, 2010, Serum S100B: a potential biomarker for suicidality in adolescents?, PloS One, 5, 10.1371/journal.pone.0011089 Goff, 2018, Association of hippocampal atrophy with duration of untreated psychosis and molecular biomarkers during initial antipsychotic treatment of first-episode psychosis, JAMA Psychiatry, 75, 370, 10.1001/jamapsychiatry.2017.4595 Gosselet, 2013, Amyloid-beta peptides, Alzheimer’s disease and the blood-brain barrier, Curr. Alzheimer Res., 10, 1015, 10.2174/15672050113106660174 Graham, 2008, Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects, Schizophr. Res., 101, 287, 10.1016/j.schres.2007.12.476 Haenisch, 2014, Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3beta signaling in bipolar patients, J. Affect. Disord., 156, 139, 10.1016/j.jad.2013.12.008 Haenisch, 2015, Multiplex immunoassay analysis of plasma shows differences in biomarkers related to manic or mixed mood states in bipolar disorder patients, J. Affect. Disord., 185, 12, 10.1016/j.jad.2015.05.065 Hartz, 2012, Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy, Stroke, 43, 514, 10.1161/STROKEAHA.111.627562 Hayes, 2014, Inflammatory molecular signature associated with infectious agents in psychosis, Schizophr. Bull., 40, 963, 10.1093/schbul/sbu052 Hendouei, 2016, Negative correlation between serum S100B and leptin levels in schizophrenic patients during treatment with clozapine and risperidone: preliminary evidence, Iran. J. Pharm. Res. (IJPR), 15, 323 Hong, 2016, Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers, Sci. Rep., 6, 27584, 10.1038/srep27584 Hozo, 2005, Estimating the mean and variance from the median, range, and the size of a sample, BMC Med. Res. Methodol., 5, 13, 10.1186/1471-2288-5-13 Kolarova, 2014, Modulation of endothelial glycocalyx structure under inflammatory conditions, Mediat. Inflamm. Krogh, 2014, The association between depressive symptoms, cognitive function, and inflammation in major depression, Brain Behav. Immun., 35, 70, 10.1016/j.bbi.2013.08.014 Kroksmark, 2018, Does s100b have a potential role in affective disorders? A literature review, Nord. J. Psychiatr., 72, 462, 10.1080/08039488.2018.1472295 Kutuzov, 2018, Contributions of the glycocalyx, endothelium, and extravascular compartment to the blood-brain barrier, Proc. Natl. Acad. Sci. U.S.A., 115, e9429, 10.1073/pnas.1802155115 Larochelle, 2011, How do immune cells overcome the blood-brain barrier in multiple sclerosis?, FEBS Lett., 585, 3770, 10.1016/j.febslet.2011.04.066 Marchi, 2012, Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches, Epilepsia, 53, 1877, 10.1111/j.1528-1167.2012.03637.x Marchi, 2003, Peripheral markers of brain damage and blood-brain barrier dysfunction, Restor. Neurol. Neurosci., 21, 109 Martin, 2018, Assessing the evidence for shared genetic risks across psychiatric disorders and traits, Psychol. Med., 48, 1759, 10.1017/S0033291717003440 Milleit, 2016, Serum S100B protein is specifically related to white matter changes in schizophrenia, Front. Cell. Neurosci., 10, 33, 10.3389/fncel.2016.00033 Morera-Fumero, 2017, Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 75, 207, 10.1016/j.pnpbp.2017.02.007 Muller, 2019, The role of intercellular adhesion molecule-1 in the pathogenesis of psychiatric disorders, Front. Pharmacol., 10, 1251, 10.3389/fphar.2019.01251 Murray, 2012, Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, 2197, 10.1016/S0140-6736(12)61689-4 Orlovska-Waast, 2019, Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis, Mol. Psychiatr., 24, 869, 10.1038/s41380-018-0220-4 Pollak, 2018, The blood-brain barrier in psychosis, Lancet Psychiatr, 5, 79, 10.1016/S2215-0366(17)30293-6 Pomara, 2014, Increased CSF matrix metalloproteinase-9 (MMP-9) and reduced white matter integrity with increasing age in late-life major depression [abstract], vol. 39, S324 Rempe, 2016, Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers, J. Cerebr. Blood Flow Metabol., 36, 1481, 10.1177/0271678X16655551 Schroeter, 2002, S100B is increased in mood disorders and may be reduced by antidepressive treatment, Neuroreport, 13, 1675, 10.1097/00001756-200209160-00021 Schroeter, 2009, Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia - original research and meta-analysis, Psychiatr. Res., 167, 66, 10.1016/j.psychres.2008.01.002 Schroeter, 2011, Glial pathology is modified by age in mood disorders - a systematic meta-analysis of serum S100B in vivo studies, J. Affect. Disord., 134, 32, 10.1016/j.jad.2010.11.008 Schumberg, 2016, Serum S100B is related to illness duration and clinical symptoms in schizophrenia-A Meta-regression analysis, Front. Cell. Neurosci., 10, 46, 10.3389/fncel.2016.00046 Steiner, 2010, S100B serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance, Cardiovasc. Psychiatry Neurol, 10.1155/2010/480707 Sweeney, 2018, Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders, Nat. Rev. Neurol., 14, 133, 10.1038/nrneurol.2017.188 Tao, 2019, Chronic food antigen-specific IgG-mediated hypersensitivity reaction as a risk factor for adolescent depressive disorder, Dev. Reprod. Biol., 17, 183 Veksler, 2014, Blood-brain barrier imaging in human neuropathologies, Arch. Med. Res., 45, 646, 10.1016/j.arcmed.2014.11.016 Wetterslev, 2009, Estimating required information size by quantifying diversity in random-effects model meta-analyses, BMC Med. Res. Methodol., 9, 86, 10.1186/1471-2288-9-86 World Health Organization, 1992 Xiong, 2014, Combining serum protein concentrations to diagnose schizophrenia: a preliminary exploration, J. Clin. Psychiatr., 75, e794, 10.4088/JCP.13m08772 Yamamori, 2013, Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine, Neurosci. Lett., 556, 37, 10.1016/j.neulet.2013.09.059 Yang, 2011, Blood-brain barrier breakdown in acute and chronic cerebrovascular disease, Stroke, 42, 3323, 10.1161/STROKEAHA.110.608257 Zlokovic, 2011, Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders, Nat. Rev. Neurosci., 12, 723, 10.1038/nrn3114